

IN THE CLAIMS:

Claims 1, 14, 16, 17, 19, 33, and 38 have been amended herein. Claims 10, 15, 18, 21, 24, 31, 32, and 34 have been cancelled herein. New claims 42 through 47 have been added. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings in the application. Please enter these claims as amended.

Listing of the Claims

1. (Currently Amended) A method of determining whether a treatment is effective in ~~changing a~~ counteracting a status of Kaposi's Sarcoma tumor cells in an individual said method comprising:

obtaining a sample from said individual after initiating said treatment;

determining whether said sample comprises a change in level of expression products of SEQ ID NOS: 72 and 81 as compared to the level of expression products of SEQ ID NOS: 72 and 81 in a sample from the individual prior to the treatment; and

determining whether the amount of the expression products of SEQ ID NOS: 72 and 81 are at least two fold reduced as compared to the amount of the expression products of SEQ ID NOS: 72 and 81 in the sample from the individual prior to said treatment, wherein an at least two fold reduction indicates that said treatment is effective in counteracting Kaposi's Sarcoma tumor cells in the individual.~~wherein said change in the level of the expression products indicates whether said treatment is effective in changing the status of said tumor cells.~~

2. (Cancelled)

3. (Previously Presented) The method according to claim 1, wherein said sample comprises at least one of said Kaposi's Sarcoma tumor cells.

4. (Previously Presented) The method according to claim 1, wherein said sample is obtained within one week of initiating said treatment.

5. (Previously Presented) The method according to claim 1, wherein said sample is obtained within two days of initiating said treatment.
6. (Cancelled)
7. (Withdrawn) The method according to claim 1, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31.
8. (Cancelled)
9. (Previously Presented) The method according to claim 1, wherein expression of SEQ ID NOS: 72 and 81 is quantified.
10. (Cancelled)
11. (Cancelled)
12. (Previously Presented) A method of detecting expression products of SEQ ID NOS: 72 and 81 said method comprising:
obtaining a sample from an individual;
introducing nucleic acids to said sample, said nucleic acids comprising: SEQ ID NO: 72 and SEQ ID NO: 81;
hybridizing said nucleic acids to said expression products in said
sample; and
detecting the hybridized molecules.

13. (Withdrawn) A method of detecting an expression product of a marker gene comprising: incubating a proteinaceous molecule to a sample from an individual, said proteinaceous molecule capable of specifically binding a protein encoded by a nucleic acid selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof; and detecting binding between said proteinaceous molecule and said protein.

14. (Currently Amended) The method according to claim 12, further comprising determining whether said SEQ ID NOS: 72 and 81 are at least two fold overexpressed as compared to the expression provide of SEQ ID NOS: 72 and 81 in an individual without Kaposi's Sarcoma tumor cell, wherein at least two fold overexpression indicates the presence of a Kaposi's Sarcoma tumor cell~~determining the presence of a tumor cell in said individual.~~

15. (Cancelled)

16. (Currently Amended) The method according to claim 12, further comprising determining whether said sample comprises a change in level of expression products of SEQ ID NOS: 72 and 81 as compared to the level of expression products of SEQ ID NOS: 72 and 81 in a sample from the individual prior to a treatment; and
determining whether the amount of the expression products of SEQ ID NOS: 72 and 81 are at least two fold reduced as compared to the amount of the expression products of SEQ ID NOS: 72 and 81 in the sample from the individual prior to said treatment, wherein an at least two fold reduction indicates that said treatment is effective in changing the status of Kaposi's Sarcoma tumor cells in the individual~~determining whether a treatment is effective in changing the status of a certain set of target cells in said individual.~~

17. (Currently Amended) The method according to claim 12, further comprising determining whether said sample comprises a change in level of expression products of SEQ ID NOS: 72 and 81 as compared to the level of expression products of SEQ ID NOS: 72 and 81 in a sample from the individual prior to a treatment; and
determining whether the amount of the expression products of SEQ ID NOS: 72 and 81 are at

least two fold reduced as compared to the amount of the expression products of SEQ ID NOS: 72 and 81 in the sample from the individual prior to said treatment, wherein an at least two fold reduction indicates that said treatment is effective in counteracting a Kaposi's Sarcoma tumor cell in the individual ~~determining whether a treatment is effective in counteracting a tumor in said individual.~~

18. (Cancelled)

19. (Currently Amended) A method for determining whether an individual possesses a Kaposi's Sarcoma tumor cell ~~and/or a site of angiogenesis~~, said method comprising:
obtaining a sample from said individual; ~~and~~
determining whether said sample comprises expression products of ~~SialoAdhesin~~ Siglec-1, genbank number XM 016245 and TIE 1, genbank number XM 002037; and
determining whether said Siglec-1 and said TIE 1 are at least two fold overexpressed as compared to an expression profile of an individual without a Kaposi's Sarcoma tumor cell, wherein at least two fold overexpression indicates the presence of a Kaposi's Sarcoma tumor cell. ~~wherein the levels of said expression products indicates the presence or absence of a tumor cell and/or a site of angiogenesis.~~

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Withdrawn) A method of determining whether a treatment is effective in altering an angiogenic process in an individual comprising:

obtaining a first sample from said individual before initiating said treatment;

obtaining a second sample from said individual after initiating said treatment; and

comparing expression of an expression product of at least one marker gene in said first sample and said second sample.

26. (Withdrawn) The method according to claim 25, wherein said treatment comprises counteracting angiogenesis in said individual.

27. (Withdrawn) The method according to claim 25, wherein said at least one marker gene comprises a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof.

28. (Withdrawn) The method according to claim 25, wherein said treatment involves the use of at least one drug selected from the group consisting of 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC44047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat, Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470, and Vitaxin.

29. (Previously Presented) The method according to claim 1, wherein said sample is a blood sample.

30. (Previously Presented) The method according to claim 1, wherein said sample comprises a peripheral blood mononuclear cell.

31. (Cancelled)

32. (Cancelled)

33. (Currently Amended) A method of determining the presence of a Kaposi's Sarcoma tumor cell in an individual comprising:
obtaining a sample from said individual;
detecting levels of peripheral blood mononuclear cell expression in the sample of SEQ ID NO: 72 and SEQ ID NO: 81; and
using the levels of detected expression to determine the presence or absence of a Kaposi's Sarcoma tumor in an individual wherein at least two fold overexpression of SEQ ID NOS: 72 and 81 as compared to the expression profile of SEQ ID NOS: 72 and 81 in an individual without Kaposi's Sarcoma tumor cell indicates the presence of a Kaposi's Sarcoma tumor cell in the individual.

34. (Cancelled)

35. (Withdrawn) A diagnostic kit comprising a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOS:1-31 and 65-82, or a part or analogue thereof, and a proteinaceous molecule capable of specifically binding a protein encoded by said nucleic acid or said part or analogue thereof.

36. (Withdrawn) The diagnostic kit according to claim 35, further comprising at least one of SEQ ID NOS:6, 18, 30, 66, 72, and 81, or a part or analogue thereof.

37. (Withdrawn) A method of determining whether a treatment is effective in changing the status of a certain set of target cells in an individual and/or altering an angiogenic process in an individual, said method comprising:
providing the diagnostic kit according to claim 35;
obtaining a sample from said individual; and
detecting the presence of an expression product of at least one marker gene in said sample.

38. (Currently Amended) A method of determining whether an individual possesses a Kaposi's Sarcoma tumor cell ~~and/or a site of angiogenesis~~, said method comprising:
providing a diagnostic kit comprising:
nucleic acids comprising SEQ ID NO: 72 and SEQ ID NO:81; and/or
~~proteinaceous molecules capable of specifically bind to SialoAdhesin or TIE-1; and~~
obtaining a sample from said individual;
quantifying expression products of SEQ ID NOS: 72 and 81 in said sample and
determining whether said SEQ ID NOS: 72 and 81 are at least two fold overexpressed as compared to the expression provide of SEQ ID NOS: 72 and 81 in an individual without Kaposi's Sarcoma tumor cell, wherein at least two fold overexpression indicates the presence of a Kaposi's Sarcoma tumor cell, using the quantification of SEQ ID NOS: 72 and 81 to determine whether the individual posses a tumor cell and/or a site of angiogenesis.

39. (Withdrawn) A method for identifying desired drug activity comprising:
determining an expression pattern of a marker gene in cells;
incubating said cells with an expression product of a gene comprising one of SEQ ID NOS:1-31 and 65-82; and
detecting an alteration in said expression pattern of said marker gene after said incubating.

40. (Withdrawn) A compound capable of altering the activity of at least one of SEQ ID NOS:66, 72, and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell.

41. (Withdrawn) A method of preparing a medicament comprising:
identifying a compound capable of altering the activity of at least one of SEQ ID NOS:66, 72, and 81, and the expression of at least one of SEQ ID NOS:66, 72, and 81 in a cell; and
incorporating said identified compound into a medicament.
42. (New) The method according to claim 1, comprising determining whether the amount of expression product of SEQ ID NO: 72 is 2-5 fold reduced as compared to the amount of expression product of SEQ ID NO: 72 in a sample from said individual prior to the treatment.
43. (New) The method according to claim 1, comprising determining whether the amount of expression product of SEQ ID NO: 81 is 2-10 fold reduced as compared to the amount of expression product of SEQ ID NO: 81 in a sample from said individual prior to the treatment.
44. (New) The method according to claim 19, comprising determining whether Siglec-1 is 2-10 fold overexpressed as compared to an expression profile of an individual without a Kaposi's Sarcoma tumor cell.
45. (New) The method according to claim 19, comprising determining whether TIE-1 is 2-5 fold overexpressed as compared to an expression profile of an individual without a Kaposi's Sarcoma tumor cell.
46. (New) The method according to claim 38, comprising determining whether SEQ ID NO: 81 is 2-10 fold overexpressed as compared to an expression profile of an individual without a Kaposi's Sarcoma tumor cell.
47. (New) The method according to claim 38, comprising determining whether SEQ ID NO: 72 is 2-5 fold overexpressed as compared to an expression profile of an individual without a Kaposi's Sarcoma tumor cell.